Esther Rajavelu - 03 Feb 2025 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)

Role
CFO & CBO
Signature
/s/ Maegan Deare, Attorney-in-Fact for Esther Rajavelu
Issuer symbol
SPRO
Transactions as of
03 Feb 2025
Net transactions value
-$16,137
Form type
4
Filing time
05 Feb 2025, 20:52:39 UTC
Previous filing
12 Nov 2024
Next filing
06 May 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPRO Common Stock Award $0 +266,139 +70% $0.000000 645,409 03 Feb 2025 Direct F1
transaction SPRO Common Stock Award $0 +100,000 +15% $0.000000 745,409 03 Feb 2025 Direct F2
transaction SPRO Common Stock Sale $16,137 -20,689 -2.8% $0.7800 724,720 05 Feb 2025 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 3, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
F2 Each RSU represents the right to receive one share of common stock upon vesting. The RSUs shall vest in full on February 3, 2026, subject to the Reporting Person's continued service through the applicable vesting date.
F3 The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2024.

Remarks:

Interim President & CEO